EOLS Q4 2025 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

Q4 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$88M+11.6% YoY

Gross Profit

$59M67.3% margin

Operating Income

$4M4.8% margin

Net Income

$130,0000.1% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

+27.7%

Cash Flow

Operating Cash Flow

$0

Free Cash Flow

$0

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$226M

Total Liabilities

$249M

Stockholders' Equity

-$23M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$88M	$79M	+11.6%
Gross Profit	$59M	$50M	+17.8%
Operating Income	$4M	-$2M	+282.4%
Net Income	$130,000	-$7M	+101.9%

Revenue Segments

Product

$89M99%

Service

$1M1%